Abbott Laboratories ($ABT) Stock Forecast: Down 5.7% Today

What is Abbott Laboratories?

Abbott Laboratories (NYSE: ABT) operates as a global healthcare company specializing in medical devices, diagnostics, generic medicines, and nutritional products. A recent acquisition of Exact Sciences has had a significant impact on the company's financial prospects.

Why is Abbott Laboratories going down?

ABT stock is down 5.7% on Apr 16, 2026 19:06

• ABT stock decreased by 3.2% today, reflecting bearish movement.
• The market's reaction was unfavorable due to Abbott Laboratories revising its 2026 earnings forecast downward, primarily due to the acquisition of Exact Sciences focusing on oncology diagnostics.
• Despite the company meeting expectations for Q1 adjusted EPS and projecting accelerated growth in the latter half of the year, concerns regarding the short-term earnings dilution from the acquisition and challenges in the nutrition sector led to a decline in stock value.
• The costs associated with the acquisition and difficulties in the nutrition division have seemingly outweighed the positive aspects of Abbott's performance, resulting in the stock's downward trend.

ABT Price Chart

ABT Technical Analysis

ABT News

S&P 500, Nasdaq 100 Hit New Records On Trump's Ceasefire Efforts - Apple (NASDAQ:AAPL), Abbott Laboratori

The S&P 500 and Nasdaq 100 reached new record highs on Thursday, with the S&P 500 advancing to 7,038.57 and the Nasdaq 100 rallying 0.6% to 26,359. This surge is attributed to optimism surrounding President Donald Trump's declared 10-day ceasefire between Israeli and Lebanese leaders. Despite rising oil prices due to potential Hormuz toll legislation, the market reacted positively to the ceasefire news, with the energy and tech sectors showing strong performance while healthcare declined.

https://www.benzinga.com/markets/market-summary/26/04/51866579/sp-500-nasdaq-100-record-highs-oil-surges-trump-israel-lebanon-ceasefire-markets-thursday

Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag

Abbott Laboratories shares fell 3.2% despite marginally beating Wall Street's profit and revenue estimates for the first quarter. The decline was largely due to a lowered 2026 earnings outlook, impacted by the recently completed $23 billion acquisition of Exact Sciences for oncology diagnostics. While the acquisition establishes Abbott as a leader in a high-growth segment, it is expected to dilute near-term earnings by about $0.20 per share.

https://www.proactiveinvestors.com/companies/news/1090692/abbott-labs-shares-fall-as-earnings-beat-offset-by-exact-sciences-acquisition-drag-1090692.html

Transcript: Abbott Laboratories Q1 2026 Earnings Conference Call - Abbott Laboratories (NYSE:ABT)

Abbott Laboratories reported Q1 adjusted EPS of $1.15, meeting expectations despite financing costs and a weaker respiratory season. The acquisition of Exact Sciences is expected to add $3 billion in sales for 2026 and accelerate long-term growth, with new medical device launches and clinical trials planned to expand technological offerings. The company anticipates accelerated growth in the second half of the year, driven by nutrition strategy execution, diagnostics, and Exact Sciences integration, projecting 6.5% to 7.5% comparable sales growth for 2026.

https://www.benzinga.com/insights/news/26/04/51860130/transcript-abbott-laboratories-q1-2026-earnings-conference-call

Abbott cuts profit forecast in wake of Exact Sciences deal

Abbott Laboratories has reduced its profit forecast following its deal with Exact Sciences. The company announced this change on April 16, 2026. The adjustment reflects the financial implications of the recent acquisition.

https://www.modernhealthcare.com/medical-devices/mh-abbott-laboratories-profit-forecast-exact-sciences/

Abbott Stock Tumbles on Earnings. Nutrition Business Is Struggling and Merger Costs Biting.

Abbott Laboratories reported first-quarter earnings that slightly exceeded analyst expectations, but its shares fell. This decline was attributed to persistent struggles in its nutrition business and the anticipated dilutive impact of its acquisition of Exact Sciences on full-year earnings.

https://www.barrons.com/articles/abbott-labs-earnings-stock-price-c7c75582

Trending Today

Crude Oil ($CRUDE) Commodity Forecast: Down 5.1% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.2% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Down 10.3% Today

DaVita Inc. ($DVA) Stock Forecast: Up 5.1% Today

Skyworks Solutions Inc. ($SWKS) Stock Forecast: Up 5.2% Today

Coty Inc. Class A ($COTY) Stock Forecast: Up 5.6% Today

Rockwell Automation Inc. ($ROK) Stock Forecast: Up 8.9% Today

Intel Corporation ($INTC) Stock Forecast: Up 11.7% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 5.5% Today

Abbott Laboratories Price History

05.00.2026 - ABT Stock was up 1.3%

• ABT witnessed a significant bullish movement today.
• This trend may be linked to the recent rise in institutional holdings by Asset Management One Co. Ltd., suggesting confidence in the company's performance and future prospects.
• Furthermore, Abbott Laboratories disclosed strong Q3 earnings, increased its quarterly dividend, and garnered a "Moderate Buy" consensus rating from analysts, likely contributing to market optimism and heightened investor interest in the stock.
• The positive institutional investment activity and favorable financial performance indicators have driven ABT's stock price higher today.

16.03.2026 - ABT Stock was down 5.3%

• Strong first-quarter 2026 results were reported by Abbott Laboratories, with net sales up 7.8% year over year and adjusted diluted EPS rising by 6% to $1.15.
• Despite the positive earnings, ABT experienced a bearish movement, falling 3.2% due to concerns over the impact of the recently completed $23 billion acquisition of Exact Sciences on its earnings outlook for 2026.
• The acquisition of Exact Sciences is expected to position Abbott as a leader in the oncology diagnostics market, but the near-term earnings dilution of about $0.20 per share contributed to the stock's decline.
• The struggles in Abbott's nutrition business and the merger costs associated with Exact Sciences were key factors contributing to the bearish movement in ABT's stock price despite the positive earnings beat.

16.03.2026 - ABT Stock was down 5.7%

• ABT stock decreased by 3.2% today, reflecting bearish movement.
• The market's reaction was unfavorable due to Abbott Laboratories revising its 2026 earnings forecast downward, primarily due to the acquisition of Exact Sciences focusing on oncology diagnostics.
• Despite the company meeting expectations for Q1 adjusted EPS and projecting accelerated growth in the latter half of the year, concerns regarding the short-term earnings dilution from the acquisition and challenges in the nutrition sector led to a decline in stock value.
• The costs associated with the acquisition and difficulties in the nutrition division have seemingly outweighed the positive aspects of Abbott's performance, resulting in the stock's downward trend.

22.00.2026 - ABT Stock was down 10.2%

• ABT stock saw a significant decline of 7% post its latest financial results announcement.
• The market responded unfavorably to ABT's sales figure of $11.46 billion, which fell below the analyst forecast of $11.8 billion.
• The market is wary of the impact of the proposed $23 billion acquisition deal with Exact Sciences (EXAS) on ABT's stock performance.
• Though the company's earnings per share for the fourth quarter aligned with analyst predictions, the lower-than-expected sales figures have shaken investor confidence.

22.00.2026 - ABT Stock was down 8.7%

• Abbott Laboratories (ABT) stock plummeted by 7% due to fourth-quarter sales falling short of analyst expectations, despite meeting EPS estimates.
• The pending $23 billion buyout deal with Exact Sciences (EXAS) added uncertainty and pressure on ABT's stock performance.
• The Medical Devices segment showed strong growth with a 12.3% increase in sales, but the overall revenue miss affected the stock negatively.
• The disappointing financial results and underwhelming sales figures are the main drivers behind the bearish movement of Abbott Laboratories' stock today.

22.00.2026 - ABT Stock was down 9.8%

• Abbott Laboratories (ABT) stock experienced a significant bearish movement, dropping 7% in response to its fourth-quarter financial results falling short of analyst expectations.
• The disappointment in sales figures, missing the $11.8 billion estimate, led to a loss in investor confidence and contributed to the stock slump.
• The looming $23 billion buyout deal with Exact Sciences added to the market uncertainty surrounding Abbott's future prospects, further impacting the bearish sentiment.
• Despite meeting EPS estimates and showcasing strong performance in its Medical Devices business with a 12.3% sales increase, the overall revenue miss overshadowed these positive aspects and drove the stock price down.